Buckley Wealth Management LLC Acquires New Holdings in Celgene Co. (CELG)
Buckley Wealth Management LLC acquired a new stake in Celgene Co. (NASDAQ:CELG) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 7,254 shares of the biopharmaceutical company’s stock, valued at approximately $757,000.
Several other large investors also recently added to or reduced their stakes in CELG. Janus Henderson Group PLC increased its holdings in shares of Celgene by 4,290.5% in the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after purchasing an additional 8,217,433 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Celgene by 1,489.2% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after purchasing an additional 1,787,052 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Celgene by 11.5% in the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock valued at $2,181,818,000 after purchasing an additional 1,546,673 shares during the last quarter. Hedge funds and other institutional investors own 78.60% of the company’s stock.
CELG has been the topic of several research reports. Cantor Fitzgerald set a $112.00 price objective on shares of Celgene and gave the company a “hold” rating in a report on Wednesday, January 17th. William Blair reiterated a “buy” rating on shares of Celgene in a report on Wednesday, February 28th. BMO Capital Markets reiterated a “buy” rating and issued a $147.00 price objective on shares of Celgene in a report on Friday, December 22nd. Credit Suisse Group set a $129.00 price target on shares of Celgene and gave the company a “buy” rating in a research note on Thursday, March 1st. Finally, Stifel Nicolaus set a $130.00 price target on shares of Celgene and gave the company a “buy” rating in a research note on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Celgene presently has a consensus rating of “Buy” and a consensus price target of $128.22.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. The firm had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The business’s revenue for the quarter was up 16.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.61 earnings per share. equities analysts predict that Celgene Co. will post 7.66 EPS for the current fiscal year.
Celgene declared that its board has approved a share repurchase program on Wednesday, February 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.
In other news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $95.99, for a total value of $887,907.50. Following the completion of the transaction, the director now owns 94,801 shares of the company’s stock, valued at $9,099,947.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ernest Mario sold 13,370 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $94.49, for a total transaction of $1,263,331.30. The disclosure for this sale can be found here. Insiders sold 41,120 shares of company stock valued at $3,879,509 in the last three months. Company insiders own 0.95% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Buckley Wealth Management LLC Acquires New Holdings in Celgene Co. (CELG)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/buckley-wealth-management-llc-acquires-new-holdings-in-celgene-co-celg/1948322.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.